香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性或完 整性亦不發表任何聲明，並明確表示概不因本公告全部或任何部份內容而產生或因依賴該等內容而 引致的任何損失承擔任何責任。 須予披露的交易 認購中國銀行結構性存款產品 認購結構性存款產品 近日，本公司與中國銀行訂立中國銀行結構性存款產品協議 I 及中國銀行結構性存款產品協議 II，同意以 A 股公開發行所得暫時閑置募集資金向中國銀行認購總金額為人民幣 1.80 億元的結構 性存款產品。 上市規則的涵義 - 1 - 中國銀行結構性存款產品協議 本公司與中國銀行訂立之两份結構性存款產品協議（有關結構性存款產品均由本公司以 A 股公開發 行所得暫時閑置募集資金認購）的主要條款大致相同，載列如下： | 產品期限： | 協議 | | 期限 | | --- | --- | --- | --- | | | 中國銀行結構性存款產品協議 | I | 天 79 | | | 中國銀行結構性存款產品協議 | II | 78 天 | | 認購本金及預期 | 協議 | 本金 | 預期年化收益率範圍 | | 年化收益率： | 中國銀行結構性存款產品 | 人民 ...

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性或完 整性亦不發表任何聲明，並明確表示概不因本公告全部或任何部份內容而產生或因依賴該等內容而 引致的任何損失承擔任何責任。 須予披露的交易 認購平安銀行結構性存款產品 認購結構性存款產品 近日，本公司與平安銀行訂立平安銀行結構性存款產品協議 I，同意以日常營運產生的自有閑置 資金向平安銀行認購總金額為人民幣 3.00 億元的結構性存款產品；並與平安銀行訂立平安銀行結 構性存款產品協議 II，同意以 A 股公開發行所得暫時閑置募集資金向平安銀行認購總金額為人民 幣 0.57 億元的結構性存款產品。 上市規則的涵義 根據上市規則第 14.22 條，平安銀行結構性存款產品協議項下的交易需合併計算。在訂立平安銀 行結構性存款產品協議時，就平安銀行結構性存款產品協議項下產品的總認購金額合計而言，一 項或多項適用百分比率（定義見上市規則第 14.07 條）超過 5%但均低於 25%，故根據上市規則第 14章，该等交易構成本公司之須予披露的交易，須遵守上市規則第14章有關申報及公告之規定， 惟獲豁免遵守獨立股東批准之規定。 概述 近日，本公司 ...

股票代码：688505 股票简称：复旦张江 公告编号：临 2023-045 上海复旦张江生物医药股份有限公司 关于参加 2023 年半年度制药及生物制品行业 集体业绩说明会的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重 大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 会议线上交流时间：2023 年 09 月 07 日（周四）下午 13:00-15:00 会议召开方式：线上文字互动 线上文字互动平台：上海证券交易所上证路演中心（http://roadshow.sseinfo.com/） 投资者可于 2023 年 09 月 06 日（周三）16:00 前通过邮件、电话、传真等形 式将需要了解和关注的问题提前提供给公司。公司将在说明会上对投资者普遍 关注的问题进行回答。 上海复旦张江生物医药股份有限公司（以下简称"公司"）已于 2023 年 8 月 11 日于上海证券交易所网站（www.sse.com.cn）披露了《上海复旦张江生物医 药股份有限公司 2023 年半年度报告》。为便于广大投资者全面深入地了解公司 2023 年半年度经营成果、财务状况及发 ...

Financial Performance - The company reported a revenue of RMB 522.83 million for the first half of 2023, representing a 92.74% increase compared to RMB 271.26 million in the same period last year[6]. - Net profit attributable to shareholders was RMB 68.44 million, a significant recovery from a loss of RMB 35.97 million in the previous year[6]. - Basic earnings per share for the first half of 2023 were RMB 0.07, compared to a loss of RMB 0.03 per share in the same period last year[7]. - The company achieved a revenue of CNY 523 million during the reporting period, representing a year-on-year growth of 92.74%[43]. - The total comprehensive income for the period was RMB 68.50 million, a significant improvement from a loss of RMB 36.73 million in the previous year[140]. - The company reported a gross profit of RMB 481.25 million, with a gross margin of approximately 92%[139]. - The company reported a total cash inflow from operating activities of RMB 416,844,233, up from RMB 397,751,452 in the previous year[145]. Cash Flow and Liquidity - The company's net cash flow from operating activities was negative RMB 108.75 million, a decline from a positive RMB 59.37 million in the same period last year, indicating a 283.19% decrease[6]. - Cash and cash equivalents stood at RMB 1,231,128,499 as of June 30, 2023, indicating strong liquidity[60]. - The cash balance at the end of June 30, 2023, was RMB 1,148,276,143, compared to RMB 1,084,972,748 at the end of June 30, 2022[147]. - The company experienced a net cash decrease of RMB 39,492,994 during the period, contrasting with an increase of RMB 1,713,377 in the same period last year[147]. Research and Development - The research and development expenditure accounted for 22.68% of the operating revenue, a decrease of 16.71 percentage points from 39.39% in the previous year[7]. - Research and development expenses for the current period amounted to approximately CNY 118.59 million, representing a 10.99% increase compared to the previous year[32]. - The company has established advanced research and development platforms, including gene engineering, photodynamic technology, and nanotechnology, focusing strategically on photodynamic drugs and antibody-drug conjugates[20]. - The company has developed multiple products based on its gene engineering technology platform, including cytokines, fusion proteins, monoclonal antibodies, and antibody-drug conjugates (ADCs) to address unmet clinical needs[21]. Market and Industry Trends - The prevalence of skin diseases in China has been increasing, with approximately 150 million patients reported[12]. - The market size for broad skin disease treatment and care in China grew from RMB 300.4 billion in 2017 to RMB 471.8 billion in 2021, with a compound annual growth rate (CAGR) of 11.95%[12]. - The global pharmaceutical market is projected to grow at a CAGR of 3-6% from 2023 to 2027, potentially reaching approximately USD 1.9 trillion[12]. - The incidence of malignant tumors in China is significant, with lung cancer being the most prevalent, accounting for a large portion of new cases[15]. Product Development and Innovation - The company aims to be an innovator and leader in the biopharmaceutical industry, focusing on exploring clinical treatment gaps and providing effective therapeutic solutions[11]. - The company’s photodynamic therapy products have filled a significant treatment gap for specific areas, such as the urethra and anal canal, where effective therapies were previously lacking[17]. - The company is focusing on the clinical application of ALA-fluorescence-guided techniques for surgical procedures, particularly for brain gliomas and bladder cancer[24]. - The company aims to leverage the unique advantages of photodynamic drugs to develop new therapeutic solutions for currently untreatable diseases[23]. Corporate Governance and Management - The company has complied with all applicable provisions of the corporate governance code, except for the separation of the roles of chairman and CEO[92]. - The company aims to enhance its governance structure and establish a long-term incentive mechanism to attract and retain management and core technical personnel[79]. - The company has appointed new executives, including a new executive director and vice president, as of May 30, 2023[82]. - The audit committee reviewed the financial performance and ensured compliance with applicable accounting standards and Hong Kong listing rules[90]. Environmental Responsibility - The company invested ¥1.0397 million in environmental protection during the reporting period[96]. - The company has established a comprehensive environmental management system, including regular monitoring of wastewater and air emissions[96]. - The company has implemented strict waste management protocols, including registration with local solid waste management systems[97]. - The company has not faced any administrative penalties related to environmental issues during the reporting period[96]. Shareholder Information - The company has a total of 38 million restricted stock options under the incentive plan, with 32.77 million shares granted in the first grant and 5.23 million shares reserved for future grants[79]. - The company reported a total of 38 million shares granted under the equity incentive plan, with 14.7 million shares becoming invalid due to unmet performance targets or employee departures[82]. - The company completed the registration of the first vesting period shares of the restricted stock incentive plan on May 12, 2023, issuing 7,572,100 A-shares[79]. - The top ten shareholders hold a total of 1,000,000,000 shares, representing approximately 97.16% of the total shares[119].

关于注销部分募集资金专户的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重 大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 股票代码：688505 股票简称：复旦张江 编号：临 2023-044 上海复旦张江生物医药股份有限公司 根据中国证监会于 2020 年 5 月 14 日出具的《关于同意上海复旦张江生物医 药股份有限公司首次公开发行股票注册的批复》（证监许可[2020]912 号），同意 公司首次公开发行股票的注册申请。公司本次公开发行人民币普通股 12,000 万 股，本次发行价格为人民币 8.95 元/股，募集资金总额为人民币 107,400.00 万元， 扣除本次发行费用人民币9,967.61万元，募集资金净额为人民币97,432.39万元。 上述募集资金已于 2020 年 6 月 12 日全部到位，并由普华永道中天会计师事务所 （特殊普通合伙）对本次发行募集资金的到账情况进行了审验，并出具了《上海 复旦张江生物医药股份有限公司首次公开发行人民币普通股 A 股验资报告》（普 根据公司披露的《上海复旦张江生物医药股份有限公司首次公开发行 A 股 股票并在科 ...

海通证券股份有限公司 关于上海复旦张江生物医药股份有限公司 2023 年度持续督导半年度跟踪报告 | 保荐机构名称：海通证券股份有限公司 | 被保荐公司简称：复旦张江 | | --- | --- | | 保荐代表人姓名：郑乾国、刘勃延 | 被保荐公司代码：688505.SH | 经中国证券监督管理委员会《关于同意上海复旦张江生物医药股份有限公司 首次公开发行股票注册的批复》（证监许可[2020]912 号）批复，上海复旦张江 生物医药股份有限公司（以下简称"上市公司"、"公司"或"发行人"）首次公开发 行股票 12,000 万股，每股面值人民币 0.1 元，每股发行价格人民币 8.95 元，募 集资金总额为人民币 107,400.00 万元，扣除发行费用后，实际募集资金净额为人 民币 97,432.39 万元。本次发行证券已于 2020 年 6 月 19 日在上海证券交易所上 市。海通证券股份有限公司（以下简称"保荐机构"或"海通证券"）担任其持续 督导保荐机构，持续督导期间为 2020 年 6 月 19 日至 2023 年 12 月 31 日。 在 2023 年 1 月 1 日至 2023 年 6 月 30 ...

Financial Performance - The company's operating revenue for the first half of 2023 reached ¥522,827,706, representing a 92.74% increase compared to ¥271,259,675 in the same period last year[12]. - The net profit attributable to shareholders was ¥68,437,509, a significant recovery from a loss of ¥35,974,546 in the previous year[12]. - The net profit attributable to shareholders after deducting non-recurring gains and losses was ¥54,905,403, improving from a loss of ¥45,618,524 year-on-year[12]. - The net cash flow from operating activities was -¥108,754,157, a decline of 283.19% compared to ¥59,366,826 in the same period last year[12]. - The total assets at the end of the reporting period were ¥3,031,013,175, an increase of 1.85% from ¥2,976,007,272 at the end of the previous year[12]. - The net assets attributable to shareholders increased by 2.74% to ¥2,318,889,032 from ¥2,257,102,217 at the end of the previous year[12]. - The company achieved a revenue of 523 million RMB in the reporting period, representing a year-on-year growth of 92.74%[92]. - The company's total revenue for the reporting period was ¥522,827,706, representing a 92.74% increase compared to ¥271,259,675 in the previous year[107]. - The company's R&D expenses increased by 15.01% to ¥117,953,593 from ¥102,559,780 in the previous year[107]. - The company reported a significant increase in sales expenses by 86.58% to ¥249,225,184, attributed to improved sales performance[107]. - The increase in revenue is attributed to the gradual stabilization of the external environment, leading to a steady recovery in the shipment volume and terminal usage of pharmaceutical products[147]. Research and Development - The company is focusing on the development of gene engineering technology and aims to enhance clinical research and registration of gene drugs for commercialization[40]. - The company has established an oral solid dosage technology platform to shorten the industrialization project cycle, focusing on new drugs and generics with unique clinical value[46]. - The company is focusing its R&D on innovative drugs for skin diseases, tumors, and autoimmune diseases, while also exploring the field of sustained-release drugs for neurological diseases[105]. - The company has established research and development capabilities in biopharmaceuticals and small molecules, with ADC drugs expected to become a significant product group following the completion of the Taizhou ADC drug workshop[127]. - The company has a strong focus on R&D, with 173 personnel, including 7 PhDs and 67 Master's degree holders, ensuring a robust research capability[56]. - The company has established a nanotechnology platform to enhance drug solubility and targeted delivery, addressing significant technical barriers in the development of nanomedicines[45]. - The company is strategically focusing on the development of its gene engineering, photodynamic, and nanotechnology platforms[196]. - The company has completed the construction of its ADC drug workshop in Taizhou, positioning ADCs as a key product group[67]. - The company is developing new indications for hydrochloride amine pentanoic acid, which is a key research direction[43]. - The company is advancing multiple projects in clinical trials, including the use of amiodarone for treating HPV-related cervical precancerous lesions, currently in Phase IIc[71]. - The company has established a strong R&D capability in gene engineering, photodynamic therapy, and nanotechnology, targeting skin diseases and tumors[94]. - The company is focusing on the development of antibody-drug conjugates (ADC), with the first clinical trial for the anti-Trop2 antibody conjugate approved in January 2023[68]. - The company is addressing significant clinical needs in the oncology sector, with a focus on developing effective and low-toxicity anti-cancer drugs[35]. - The company is a leader in the development of photodynamic drugs, targeting conditions such as cervical precancerous lesions and bladder cancer, with a focus on unique treatment solutions for currently untreatable diseases[42]. - The company is developing new photodynamic therapy molecules to improve efficacy and overcome common defects of photosensitizers[145]. Market and Strategic Focus - The global pharmaceutical market is expected to grow at a compound annual growth rate of 3%-6% from 2023 to 2027, reaching approximately $1.9 trillion[33]. - The company aims to leverage its early strategic positioning and policy support to maintain a competitive edge in the pharmaceutical industry[56]. - The company is focusing on the domestic academic promotion of its already listed products and plans to expedite international registration in mature conditions, particularly in Europe and the United States[125]. - The company plans to conduct international registration for its already marketed drugs to strengthen its industrial development foundation[145]. - The company is currently facing risks related to the successful development and commercialization of new products, which can take over ten years and involve high costs and uncertainties[116]. - The company is actively monitoring external investment projects to balance short-term and long-term development plans, aiming to achieve growth and shareholder benefits[126]. - The company has a relatively single product variety risk, which could impact its financial performance if not addressed[119]. - The company has no controlling shareholder or actual controller, which may lead to governance instability and decision-making inefficiencies in the future[98]. Governance and Management - The company held its annual general meeting on May 30, 2023, where the eighth board of directors and non-employee representative supervisors were elected[186]. - Key personnel changes include the election of new independent non-executive directors and the appointment of new core technical personnel[185][187]. - The company has made significant changes in its management team, including the appointment of new deputy general managers[185][187]. - The company’s governance procedures for the shareholder meetings were confirmed to be compliant with legal regulations[186]. - The company has established a three-year shareholder dividend return plan for 2023-2025[185]. - The company has recognized new core technical personnel based on their professional backgrounds and contributions to R&D[187][192]. - The company is committed to maintaining a stable team of core technical personnel to sustain its competitive advantage in technology and ensure stable research and production services[116]. Production and Capacity Expansion - The company plans to expand its production capacity with the construction of the Taizhou Fudan Zhangjiang II pharmaceutical production base, covering approximately 44 acres and with a planned total construction area of about 42,000 square meters[106]. - The company is progressing steadily with the construction of its second-phase pharmaceutical production base in Taizhou, which is expected to enhance its production capacity[134]. - The fair value of other equity instruments decreased by 39.32%, amounting to 366,679 RMB[152]. - The company reported a 38.17% increase in construction in progress, totaling 169,079,236 RMB, which is 5.58% of total assets[152].

Financial Performance - The company reported a revenue of RMB 522.83 million for the first half of 2023, representing a 92.74% increase compared to RMB 271.26 million in the same period last year[5]. - Net profit attributable to shareholders was RMB 68.44 million, a significant recovery from a loss of RMB 35.97 million in the previous year[5]. - Basic earnings per share for the period were RMB 0.07, compared to a loss of RMB 0.03 per share in the same period last year[6]. - The company achieved a pre-tax profit of RMB 63.43 million, recovering from a loss of RMB 61.19 million in the same period last year[3]. - The company’s comprehensive income attributable to shareholders was RMB 68.33 million, compared to a loss of RMB 36.68 million in the same period last year[3]. - Operating revenue increased to RMB 522,827,706, a 92.74% increase compared to RMB 271,259,675 in the same period last year[51]. - The total profit for the period was RMB 63,432,798, a significant recovery from a loss of RMB 61,189,485 in the same period last year[127]. - The company reported a net loss of RMB 36,020,882 for the six months ended June 30, 2022, which highlights the financial challenges faced in that period[136]. Assets and Liabilities - The company's total assets reached RMB 3.03 billion, up 1.85% from RMB 2.98 billion at the end of the previous year[4]. - Total liabilities stood at RMB 716.04 million, slightly down from RMB 722.99 million in the previous year[4]. - Cash and cash equivalents as of June 30, 2023, totaled RMB 1,231,128,499, significantly exceeding the outstanding loan balance[54]. - The company has no asset pledges as of June 30, 2023[57]. - The total assets of Taizhou Fudan Zhangjiang Pharmaceutical Co., Ltd. are RMB 565,336,994, with a net profit of RMB 14,787,447[64]. - The company's total liabilities decreased slightly to RMB 716,037,743 from RMB 722,985,917, indicating a reduction of about 0.13%[122]. - The company’s total equity increased to RMB 2,314,975,432 from RMB 2,253,021,355, reflecting a growth of approximately 2.75%[122]. Research and Development - Research and development expenses accounted for 22.68% of revenue, a decrease of 16.71 percentage points from 39.39% in the previous year[6]. - The company has invested a total of approximately ¥118.59 million in R&D, representing a 10.99% increase compared to the previous period[30]. - The company is focusing its R&D on innovative drugs for skin diseases, tumors, and autoimmune diseases, with a strategic emphasis on photodynamic drugs and antibody-drug conjugates[48]. - The company has established a gene engineering technology platform, focusing on the development of monoclonal antibodies and antibody-drug conjugates (ADC), which are key areas for future commercialization[20]. - The company’s research and development strategy emphasizes addressing unmet clinical needs and achieving differentiated competition through innovative drug development[19]. - The company is conducting Phase I clinical trials for multiple antibody-drug conjugates (ADCs) targeting various cancers, including DM1 for CD30, SN38 for Trop2, and BB05 for Her2, with the first patient enrolled in January 2023 for the BB05 project[21]. - The company has established a nanotechnology platform, with the liposomal formulation里葆多® launched in 2009, and has received acceptance for consistency evaluation of its doxorubicin liposome injection[25]. Market and Industry Trends - The global pharmaceutical market is expected to grow at a compound annual growth rate (CAGR) of 3-6% from 2023 to 2027, reaching approximately $1.9 trillion[10]. - The Chinese pharmaceutical market's CAGR from 2016 to 2020 was 3.70%, with a total market size of $221.4 billion in 2020, projected to reach $349.8 billion by 2025 and $457.4 billion by 2030[10]. - The market for broad skin disease treatment and care in China grew from RMB 300.4 billion to RMB 471.8 billion from 2017 to 2021, with a CAGR of 11.95%[11]. - The incidence of malignant tumors remains a significant health threat, with lung cancer being the most prevalent, accounting for a substantial portion of new cases in China[14]. - The global oncology spending is projected to reach $370 billion by 2027, driven by the introduction of new drugs and biosimilars[14]. Risks and Challenges - The company faces risks related to new drug development, which can take over ten years and involve significant costs and uncertainties[43]. - The company has a risk of core technical personnel turnover, which could impact its competitive advantage and stability in R&D and production services[44]. - The company may face drug price reduction risks due to government policies and market competition, which could negatively impact revenue[47]. - The company is exposed to potential foreign exchange risks, although most transactions occur in the domestic market[46]. Corporate Governance and Shareholder Matters - The company has established a three-year dividend return plan for shareholders from 2023 to 2025[71]. - The company has completed the nomination of candidates for the eighth board of directors and the supervisory board, with elections held on May 30, 2023[72]. - The company has recognized new core technical personnel, including Li Xiaowen, Yu Daiqing, Chen Yu, and Yang Tong, based on their contributions to R&D and business development[73]. - The company has a restricted stock incentive plan that includes a total of 38 million shares, with 32.77 million shares granted in the first grant and 5.23 million shares reserved for future grants[75]. - The company has not reported any changes in controlling shareholders or actual controllers during the reporting period[119]. Environmental and Social Responsibility - The company has established a comprehensive environmental management system and adheres to national and local standards for pollutant emissions, with no violations reported during the reporting period[88][90]. - The company has implemented strict measures for wastewater treatment, ensuring compliance with the Biopharmaceutical Industry Pollutant Discharge Standards[89]. - The company is committed to sustainable development and has set five-year environmental goals based on 2020 levels to enhance its environmental management[90]. - The company has implemented carbon reduction measures, achieving a reduction of 117.651 tons of CO2 equivalent emissions[91]. Financial Management - The total amount raised from the IPO was RMB 1,074 million, with a net amount of RMB 974.32 million after deducting issuance costs[98]. - The company approved the use of RMB 96 million of excess raised funds for replenishing working capital[100]. - The company plans to manage temporarily idle raised funds, with a maximum of RMB 350 million allocated for cash management in safe and liquid investment products[101]. - The company’s financial strategies are focused on enhancing profitability and safeguarding shareholder interests[102].

股票代码：688505 股票简称：复旦张江 编号：临2023-042 上海复旦张江生物医药股份有限公司 第八届监事会第二次会议决议公告 上海复旦张江生物医药股份有限公司（以下简称"公司"）第八届监事会第二 次会议于 2023 年 7 月 27 日以书面方式发出会议通知及会议资料，于 2023 年 8 月 10 日以现场表决方式召开，由公司监事会主席黄建先生召集，会议应参加表 决的监事 3 人，实际参加表决的监事 3 人，本次会议的通知和召开符合《中华人 民共和国公司法》《上海证券交易所科创板股票上市规则》和《上海复旦张江生 物医药股份有限公司章程》（以下简称"《公司章程》"）的规定。 二、监事会会议审议情况 经与会监事审议，做出如下决议： （一）审议通过《关于公司<2023 年半年度报告><2023 年半年度报告摘要> 及<截至二零二三年六月三十日止六个月期间中期业绩公告>的议案》 公司监事会认为：《公司 2023 年半年度报告》《公司 2023 年半年度报告摘要》 及《截至二零二三年六月三十日止六个月期间中期业绩公告》的编制及审议程序 均符合法律、法规、规范性文件和《公司章程》的要求，格式和内容符合中国证 ...

上海复旦张江生物医药股份有限公司独立董事 关于第八届董事会第三次会议相关议案的独立意见 我们认为：公司 2023 年半年度募集资金存放与使用情况符合《上市公司监管 指引第 2 号—上市公司募集资金管理和使用的监管要求》《上海证券交易所科创板 上市公司自律监管指引第 1 号——规范运作》以及公司《募集资金使用管理办法》 等法律法规、规范性文件和公司制度的规定，对募集资金进行了专户存储和专项使 用，并及时履行了相关信息披露义务，募集资金具体使用情况与公司已披露情况一 致，不存在变相改变募集资金用途和损害股东利益的情况，不存在违规使用募集资 金的情况。 综上，我们同意《关于 2023 年半年度募集资金存放与实际使用情况的专项报 告的议案》。 独立董事：王宏广、林兆荣、徐培龙 2023 年 8 月 10 日 我们作为上海复旦张江生物医药股份有限公司（以下简称"公司"或"本公 司"）的独立董事，根据《上市公司独立董事规则》《上海证券交易所科创板股票 上市规则》及《上海复旦张江生物医药股份有限公司章程》等规范性文件的要求， 对公司第八届董事会第三次会议审议的相关事项，基于独立、客观、公正的判断立 场，发表如下意见： 《关 ...